MEETINGS & COURSES
Find a meeting
 FEATURED MEETINGS
  OSN NY 2010
  APAO 2010
  Hawaiian Eye 2011
  Retina 2011
  Rome 2011
  Kiawah Eye 2011
 
BREAKING NEWS
September 2, 2010

Extended dosing treatment paradigms may be associated with greater chance of visual acuity loss

VANCOUVER, British Columbia — Patients treated under extended anti-VEGF dosing protocols for choroidal neovascularization due to age-related macular degeneration may be more likely to lose visual acuity.

John T. Thompson, MD
John T. Thompson

"Office examinations less frequent than every 4 to 6 weeks combined with extended therapy should be used with caution, especially in eyes with good visual acuities after the induction phase," John T. Thompson, MD, said here at the American Society of Retina Specialists annual meeting.

In a retrospective analysis of 165 consecutive treatment-naïve patients treated by Dr. Thompson at his clinic with Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech), recurrent choroidal neovascularization frequently was associated with decreased vision during extended dosing.

Get the Whole Story
Glycemic and lipid control has protective effect on progression of diabetic retinopathy, study says
Anti-VEGF therapy may have a role in diabetic macular edema
Genetics may foretell treatment response in AMD
FDA approves 0.01% formulation of Lumigan

CUSTOM PROJECTS

Advanced Technology for Complicated Cataract Surgery

Advanced Technology for Complicated
Cataract Surgery

View all content

BOOKSTORE
  Curbside Consultation in Oculoplastics: 49 Clinical Questions
Robert C. Kersten MD; Timothy J. McCulley MD